US Broker Ratings

U.S. Physical Therapy, Inc. (USPH) Stock Analysis: A 23.09% Potential Upside in the Healthcare Sector

U.S. Physical Therapy, Inc. (NYSE: USPH) has emerged as a promising player in the healthcare sector, specifically within the medical care facilities industry. With a market capitalization of $1.32 billion,..

Astrana Health Inc. (ASTH) Stock Analysis: Impressive 36.40% Potential Upside Amid Strong Revenue Growth

Astrana Health Inc. (NASDAQ: ASTH) has been making waves in the healthcare sector, particularly within the medical care facilities industry. With a market capitalization of $1.52 billion, Astrana is proving..

10x Genomics, Inc. (TXG) Stock Analysis: Investor Outlook with 8.45% Potential Upside

10x Genomics, Inc. (NASDAQ: TXG) is capturing investor attention with its innovative contributions to the healthcare sector. Operating primarily within the Health Information Services industry, 10x Genomics stands out with..

Celldex Therapeutics (CLDX) Stock Analysis: Exploring a Potential 115% Upside in the Biotech Space

For investors keen on the biotechnology sector, Celldex Therapeutics, Inc. (NASDAQ: CLDX) represents an intriguing opportunity. With a market capitalization of $1.64 billion, this New Jersey-based biopharmaceutical company is making..

Viridian Therapeutics (VRDN) Stock Analysis: Exploring a 65% Upside Potential

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology firm situated in the healthcare sector, has been drawing considerable attention from investors, particularly due to its promising pipeline and the potential upside..

Neogen Corporation (NEOG) Stock Analysis: Understanding the 29.84% Potential Upside

Investors looking to tap into the healthcare sector’s diagnostic and research sub-industry might find Neogen Corporation (NASDAQ: NEOG) to be an intriguing candidate. With a market capitalization of $1.37 billion,..

The Pennant Group, Inc. (PNTG) Stock Analysis: Unpacking a 31.74% Upside Potential

Investors are continually seeking opportunities in the healthcare sector, and The Pennant Group, Inc. (NASDAQ: PNTG) presents an intriguing case with a notable 31.74% upside potential. This analysis delves into..

Mineralys Therapeutics, Inc. (MLYS) Stock Report: Navigating Biotech’s Potential with a 14.88% Upside

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is making waves in the healthcare sector, specifically within the biotechnology industry. With a current market cap of $3.04 billion, the company is focused on..

Vera Therapeutics, Inc. (VERA) Investor Outlook: Exploring a 141% Upside Potential

Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company, is capturing investor attention with its promising development pipeline and a substantial potential upside of 141.09%, according to analyst ratings. With..

Artivion, Inc. (AORT) Stock Analysis: Navigating a 15.3% Revenue Growth in the Medical Devices Sector

Artivion, Inc. (NASDAQ: AORT) is making waves in the healthcare sector, particularly within the medical devices industry. Headquartered in Kennesaw, Georgia, this company is renowned for its innovative products in..

Mesoblast Limited (MESO) Stock Analysis: An Investor’s Guide to a 117% Upside Potential in Biotechnology

Mesoblast Limited (NASDAQ: MESO) stands at a compelling juncture in the biotechnology sector, offering a significant potential upside of 117.26% based on current analyst ratings. This Australian company is at..

MiMedx Group, Inc (MDXG) Stock Analysis: A 62% Potential Upside Beckons Investors

Investors hunting for promising opportunities in the biotechnology sector may want to turn their attention to MiMedx Group, Inc. (MDXG). With a market capitalization of $1.11 billion, this healthcare company..

Healthcare Services Group, Inc. (HCSG): Investor Outlook with a 23.04% Potential Upside

Healthcare Services Group, Inc. (NASDAQ: HCSG) stands out in the healthcare sector with its specialized focus on providing essential services to medical care facilities across the United States. With a..

Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a 28% Upside Potential

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH), a key player in the healthcare sector with a focus on generic and proprietary pharmaceuticals, is making waves among investors with its intriguing market dynamics...

Novavax, Inc. (NVAX) Investor Outlook: Unpacking the 67% Potential Upside Amid Vaccine Innovations

For investors with a keen eye on the biotechnology sector, Novavax, Inc. (NVAX) presents a fascinating case study of potential and volatility. With a market capitalization of $1.28 billion, this..

National HealthCare Corporation (NHC) Stock Analysis: Unpacking the Potential of a Healthcare Giant with a 28.70% Revenue Surge

National HealthCare Corporation (NYSE: NHC), a powerhouse in the medical care facilities industry, commands attention with its impressive 28.70% revenue growth. As a key player in the healthcare sector, NHC..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Eye-Catching Revenue Growth and a Promising Upside

Investors eyeing Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will find a company positioned at the forefront of innovative biopharmaceutical solutions, particularly in the field of eye care. With its headquarters in..

Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Unveiling a 43.71% Potential Upside for Investors

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has been making waves in the healthcare sector with its cutting-edge medical devices tailored for diabetes management. As a mid-cap company with a market..

LifeStance Health Group, Inc. (LFST): Investor Outlook Highlights 69.38% Potential Upside

LifeStance Health Group, Inc. (NASDAQ: LFST) is capturing the attention of investors with a compelling mix of growth potential and strong analyst support, underscored by a striking potential upside of..

Travere Therapeutics, Inc. (TVTX) Stock Analysis: Strong Growth Potential Amidst Biotech Innovation

Travere Therapeutics, Inc. (NASDAQ: TVTX), a leading player in the biotechnology sector, continues to capture investor attention with its strategic focus on rare kidney and metabolic diseases. With a market..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds